A team of researchers have found that patterns of activity in the brain associated with nitrous oxide, ketamine and LSD overlap, suggesting a common underlying biology.
Cybin has announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous (IV) DMT in healthy...
The first patient in Beckley Psytech’s trial investigating its patent-protected benzoate formulation of 5-MeO-DMT – BPL-003 – as a therapy for Treatment Resistant Depression (TRD) has...
An increasing amount of research is showing psychedelics as promising treatments for a variety of mental health conditions, however, a group of experts have emphasised the...
Mind Medicine has presented positive topline data in Basel, Switzerland in April from a double-blind, investigator-initiated trial evaluating lysergide (LSD) in the treatment of Major Depressive...
Three promising studies featuring psilocybin, LSD and MDMA have shown signs of improved brain function.
More than 200 world-leading researchers in the field of psychedelics gathered at the University of Exeter for the sixth Breaking Convention.
Awakn Life Sciences and the University of Exeter (UoE) are collaborating to put in place a framework for a Phase 3 trial exploring the use of...
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent psychedelic compound found in the secretion from the parotid glands of the Bufo alvarius toad, native to the Sonoran Desert of...
After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders who are looking to transform the...